Literature DB >> 29306022

T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients.

P Di Gennaro1, G Gerlini2, R Caporale3, S Sestini2, P Brandani2, C Urso4, N Pimpinelli5, L Borgognoni2.   

Abstract

T regulatory cells (Tregs), involved in tumour tolerance, can generate Adenosine by CD39/CD73 surface enzymes, which identify four Tregs subsets: CD39+CD73- nTregs, CD39+CD73+ iTregs, CD39-CD73+ oTregs and CD39-CD73- xTregs. In melanoma patients, increased Tregs levels are detected in peripheral blood (PB), sentinel lymph node (SLN) and tumour infiltrating lymphocytes (TILs), but Adenosine role was not investigated yet. We examined total Tregs and Adenosine subsets in PB, SLN and TILs from melanoma patients (n = 32) and PB from healthy donors (HD; n = 10) by flow cytometry. Total Tregs significantly increased in stage III-IV patients PB, in SLN and TILs, as compared to HD/stage I-II patients. Tregs subsets analyses showed that: 1) PB nTregs significantly increased in SLN and decreased in TILs; 2) iTregs significantly increased in stage III-IV patients PB and further significantly increased in SLN and TILs; 3) PB oTregs and xTregs significantly decreased in SLN and TILs. Patients clinical features did not significantly influence total Tregs, except SLN excision order. Results confirmed Tregs role in melanoma progression and indicate Adenosine generation as a novel escape mechanism, being nTregs and iTregs increased in PB/SLN/TILs.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenosine; Melanoma; Sentinel lymph node; TILs; Tregs

Mesh:

Substances:

Year:  2018        PMID: 29306022     DOI: 10.1016/j.canlet.2017.12.032

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression.

Authors:  Isak W Tengesdal; Alberto Dinarello; Nicholas E Powers; Matthew A Burchill; Leo A B Joosten; Carlo Marchetti; Charles A Dinarello
Journal:  Front Immunol       Date:  2021-08-31       Impact factor: 8.786

2.  CD73: an emerging checkpoint for cancer immunotherapy.

Authors:  Siqi Chen; Derek A Wainwright; Jennifer D Wu; Yong Wan; Daniela E Matei; Yi Zhang; Bin Zhang
Journal:  Immunotherapy       Date:  2019-06-21       Impact factor: 4.196

Review 3.  Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity.

Authors:  Juliana Hofstätter Azambuja; Nils Ludwig; Elizandra Braganhol; Theresa L Whiteside
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

4.  Tolerogenic IDO1+CD83- Langerhans Cells in Sentinel Lymph Nodes of Patients with Melanoma.

Authors:  Gianni Gerlini; Paola Di Gennaro; Nicola Pimpinelli; Serena Sestini; Lorenzo Borgognoni
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

Review 5.  Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review.

Authors:  Barbara Kaltschmidt; Kaya E Witte; Johannes F W Greiner; Florian Weissinger; Christian Kaltschmidt
Journal:  Biomedicines       Date:  2022-01-25

Review 6.  Targeting CD73 to augment cancer immunotherapy.

Authors:  Meejeon Roh; Derek A Wainwright; Jennifer D Wu; Yong Wan; Bin Zhang
Journal:  Curr Opin Pharmacol       Date:  2020-08-07       Impact factor: 5.547

Review 7.  Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy.

Authors:  Samaneh Arab; Jamshid Hadjati
Journal:  Immune Netw       Date:  2019-08-27       Impact factor: 6.303

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.